1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties.
about
Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indicationsArachidonic acid cytochrome P450 epoxygenase pathwayOptimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacyCytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolismInhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammationPharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogsIncorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties.Structure-activity relationships of substituted oxyoxalamides as inhibitors of the human soluble epoxide hydrolase.Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.Soluble epoxide hydrolase inhibitor attenuates inflammation and airway hyperresponsiveness in mice.Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys1,3-Disubstituted and 1,3,3-trisubstituted adamantyl-ureas with isoxazole as soluble epoxide hydrolase inhibitors.Occurrence of urea-based soluble epoxide hydrolase inhibitors from the plants in the order BrassicalesStructure-activity relationships of cycloalkylamide derivatives as inhibitors of the soluble epoxide hydrolase.Design, synthesis and biological evaluation of 4-benzamidobenzoic Acid hydrazide derivatives as novel soluble epoxide hydrolase inhibitorsSalicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities.Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model.Biologically active ester derivatives as potent inhibitors of the soluble epoxide hydrolaseImpact of epoxyeicosatrienoic acids in lung ischemia-reperfusion injury.Discovery of potent non-urea inhibitors of soluble epoxide hydrolase.In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors.Soluble epoxide hydrolase deficiency or inhibition enhances murine hypoxic pulmonary vasoconstriction after lipopolysaccharide challenge.
P2860
Q24616753-27940BE3-8027-4860-B7A7-D54096828DEFQ24653023-56878406-1491-446C-AF46-B94811E5B968Q27684895-956F10A1-BE5E-4144-89EF-47D109B605C0Q28245279-13D5194E-5379-4B10-B708-BBCEAD1B33B4Q28391533-AF8EC6B4-99D9-437A-AD1D-0216FD6188E6Q28396888-CA96BBBB-CF65-4DDB-8CE8-AF6B068D260DQ33744236-8DE4B9F8-3136-4602-86D8-F394A31D69EEQ34231319-7EC4FD6F-8A4A-4C64-B0A6-206201C9C9EFQ34241120-825243FA-86D5-4A25-B45C-5CD3F59C0D6EQ34347917-59E74550-8C19-4A4A-9BED-C8F9B38ED5DCQ35207683-A4DB827F-D41E-42E2-9A76-AF3499DF6982Q36024898-3F5738E3-88B9-4C4B-8D7F-460B079E627DQ36302996-7493D06B-039A-42FA-A731-F1E3DF4B2C08Q36362984-42567F2A-5B2B-44F6-9288-2E944A4D7E44Q36453292-182E1563-FDEA-4F87-8A1E-CCA93495768DQ37687169-F009D8D9-681A-4B6B-B221-3E76498D4701Q41839063-BCE8684F-1573-4711-BFD5-13EDCDBE2BE4Q42063327-559C246C-A9B2-43A4-9463-07F315377098Q42322454-F4FCCCAA-3DD9-4B0A-93BE-C6ED91EDA67EQ42532025-547A09D1-2BD6-4DE5-828B-4E7F523DCA3AQ42547462-D0731038-56F5-48E5-ADFE-F4DD662BB918Q43160120-E7C2D38B-3162-4D90-AEAE-917370B77240Q46368082-54633186-25CF-45AE-AB8F-00186EEEDE42
P2860
1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
1,3-disubstituted ureas functi ...... ed pharmacokinetic properties.
@en
1,3-disubstituted ureas functi ...... ed pharmacokinetic properties.
@nl
type
label
1,3-disubstituted ureas functi ...... ed pharmacokinetic properties.
@en
1,3-disubstituted ureas functi ...... ed pharmacokinetic properties.
@nl
prefLabel
1,3-disubstituted ureas functi ...... ed pharmacokinetic properties.
@en
1,3-disubstituted ureas functi ...... ed pharmacokinetic properties.
@nl
P2093
P2860
P356
P1476
1,3-disubstituted ureas functi ...... ed pharmacokinetic properties.
@en
P2093
Bruce D Hammock
Christophe Morisseau
Hsing-Ju Tsai
In-Hae Kim
Takeo Kasagami
P2860
P304
P356
10.1021/JM070705C
P407
P50
P577
2007-09-26T00:00:00Z